Simulations Plus (NASDAQ:SLP) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened

Simulations Plus, Inc. (NASDAQ:SLP) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $16.43 and traded as high as $20.73. Simulations Plus shares last traded at $20.11, with a volume of 240,372 shares.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SLP. KeyCorp reissued a “sector weight” rating on shares of Simulations Plus in a research report on Wednesday, October 29th. Citigroup reiterated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Simulations Plus in a report on Wednesday, October 8th. TD Cowen restated a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Finally, Zacks Research upgraded shares of Simulations Plus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $25.00.

Simulations Plus Stock Down 3.5%

The firm has a market capitalization of $405.22 million, a price-to-earnings ratio of -6.28 and a beta of 1.09. The company has a fifty day moving average price of $18.91 and a two-hundred day moving average price of $16.43.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.05). The business had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same quarter last year, the company earned $0.17 EPS. On average, equities analysts anticipate that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Simulations Plus

A number of hedge funds and other institutional investors have recently made changes to their positions in SLP. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Simulations Plus by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock valued at $233,000 after acquiring an additional 390 shares during the period. Prudential Financial Inc. increased its holdings in shares of Simulations Plus by 5.7% in the second quarter. Prudential Financial Inc. now owns 17,213 shares of the technology company’s stock valued at $300,000 after purchasing an additional 930 shares during the period. Invesco Ltd. increased its holdings in shares of Simulations Plus by 3.8% in the second quarter. Invesco Ltd. now owns 36,452 shares of the technology company’s stock valued at $636,000 after purchasing an additional 1,323 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Simulations Plus during the second quarter worth approximately $25,000. Finally, US Bancorp DE lifted its holdings in shares of Simulations Plus by 32.5% during the third quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock worth $93,000 after purchasing an additional 1,513 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.